CIMCALTYX Trademark

Trademark Overview


On Monday, March 4, 2024, a trademark application was filed for CIMCALTYX with the United States Patent and Trademark Office. The USPTO has given the CIMCALTYX trademark a serial number of 98431234. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, October 22, 2024. This trademark is owned by Pathalys Pharma, Inc.. The CIMCALTYX trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and biological preparations for treating hemodialysis patients; calcimimetics in the nature of pharmaceuticals that mimic the action of calcium on tissues; Pharmaceutical and biological preparations for use in nephrology and endocrinology; Pharmaceutical and biological preparations for preventing, diagnosing, treating and managing diseases, disorders, and conditions of the kidneys and glands; Pharmaceutical and biological preparations for treating and managing chronic kidney disease (CKD), end stage renal disease (ESRD), secondary hyperparathyroidism (SHPT), and conditions arising from complications of kidney disease and hemodialysis; Therapeutic agents for affecting calcium-sensing receptors on cells and managing calcium levels in the body
cimcaltyx

General Information


Serial Number98431234
Word MarkCIMCALTYX
Filing DateMonday, March 4, 2024
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, October 22, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 27, 2024

Trademark Statements


Goods and ServicesPharmaceutical and biological preparations for treating hemodialysis patients; calcimimetics in the nature of pharmaceuticals that mimic the action of calcium on tissues; Pharmaceutical and biological preparations for use in nephrology and endocrinology; Pharmaceutical and biological preparations for preventing, diagnosing, treating and managing diseases, disorders, and conditions of the kidneys and glands; Pharmaceutical and biological preparations for treating and managing chronic kidney disease (CKD), end stage renal disease (ESRD), secondary hyperparathyroidism (SHPT), and conditions arising from complications of kidney disease and hemodialysis; Therapeutic agents for affecting calcium-sensing receptors on cells and managing calcium levels in the body

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, March 4, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NamePathalys Pharma, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressRaleigh, NC 27609

Party NamePathalys Pharma, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressRaleigh, NC 27609

Trademark Events


Event DateEvent Description
Monday, March 4, 2024NEW APPLICATION ENTERED
Monday, March 4, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, July 16, 2024ASSIGNED TO EXAMINER
Friday, July 19, 2024EXAMINER'S AMENDMENT ENTERED
Friday, July 19, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, July 19, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, July 19, 2024EXAMINERS AMENDMENT E-MAILED
Friday, July 19, 2024EXAMINERS AMENDMENT -WRITTEN
Wednesday, August 7, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 27, 2024PUBLISHED FOR OPPOSITION
Tuesday, August 27, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 22, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT